|
Tumor Cell Invasion
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
We report the generation of a panel of OPCML variants with representative clinical mutations and demonstrate clear phenotypic effects in vitro and in vivo including changes to anchorage-independent growth, interaction with activated cognate receptor tyrosine kinases, cellular migration, invasion in vitro and tumor growth in vivo.
|
31316070 |
2019 |
|
Adenocarcinoma
|
0.010 |
GeneticVariation
|
group |
LHGDN |
We identified thirteen loci showing significant differential DNA methylation levels between tumor and non-tumor lung; eight of these show highly significant hypermethylation in adenocarcinoma: CDH13, CDKN2A EX2, CDX2, HOXA1, OPCML, RASSF1, SFPR1, and TWIST1 (p-value < 0.0001).
|
17967182 |
2007 |
|
Schizophrenia
|
0.430 |
Biomarker
|
disease |
BEFREE |
We demonstrated a critical role of the schizophrenia-susceptible gene OPCML in spine maturation and cognitive behaviors via regulating the ephrin-EphB2-cofilin signaling pathway, providing further insights into the characteristics of schizophrenia.
|
31577955 |
2019 |
|
Malignant neoplasm of lung
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67-86% and specificity of 74-82%.
|
17967182 |
2007 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67-86% and specificity of 74-82%.
|
17967182 |
2007 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Unexpectedly, OPCML expression was downregulated in Grade 3 tumor in comparison to other groups signifying that downregulation of OPCML expression may lead to higher grade of tumor formation at the time of diagnosis of ESCC in patients.
|
30880778 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Unexpectedly, OPCML expression was downregulated in Grade 3 tumor in comparison to other groups signifying that downregulation of OPCML expression may lead to higher grade of tumor formation at the time of diagnosis of ESCC in patients.
|
30880778 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Together these data support a role for NTM and OPCML in developmental delay and potentially in cancer susceptibility.
|
23495067 |
2013 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Together these data support a role for NTM and OPCML in developmental delay and potentially in cancer susceptibility.
|
23495067 |
2013 |
|
Developmental delay (disorder)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Together these data support a role for NTM and OPCML in developmental delay and potentially in cancer susceptibility.
|
23495067 |
2013 |
|
Global developmental delay
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together these data support a role for NTM and OPCML in developmental delay and potentially in cancer susceptibility.
|
23495067 |
2013 |
|
Malignant Neoplasms
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
Thus, through functional epigenetics, we identified OPCML as a broad tumor suppressor, which is frequently inactivated by methylation in multiple malignancies.
|
18714356 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, through functional epigenetics, we identified OPCML as a broad tumor suppressor, which is frequently inactivated by methylation in multiple malignancies.
|
18714356 |
2008 |
|
Brain Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
This study demonstrates that OPCML down-regulation occurs in the majority of brain tumours tested, warranting further investigation of OPCML and other IgLONs in the development and progression of brain tumours.
|
17239010 |
2007 |
|
ovarian neoplasm
|
0.630 |
AlteredExpression
|
disease |
LHGDN |
These findings suggest that OPCML is an excellent candidate for the 11q25 ovarian cancer TSG.
|
12819783 |
2003 |
|
Malignant neoplasm of ovary
|
0.610 |
GeneticVariation
|
disease |
UNIPROT |
These findings suggest that OPCML is an excellent candidate for the 11q25 ovarian cancer TSG.
|
12819783 |
2003 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate a novel mechanism of OPCML-mediated tumor suppression and provide a proof-of-concept for recombinant OPCML protein therapy in epithelial ovarian cancers.
|
22585860 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings demonstrate a novel mechanism of OPCML-mediated tumor suppression and provide a proof-of-concept for recombinant OPCML protein therapy in epithelial ovarian cancers.
|
22585860 |
2012 |
|
Schizophrenia
|
0.430 |
Biomarker
|
disease |
BEFREE |
Therefore, the OPCML gene is considered to be a schizophrenia-susceptible gene in the Thai population.
|
21833655 |
2012 |
|
Schizophrenia
|
0.430 |
Biomarker
|
disease |
PSYGENET |
Therefore, the OPCML gene is considered to be a schizophrenia-susceptible gene in the Thai population.
|
21833655 |
2012 |
|
Fatty Liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The up-regulation of expression of hepatic genes related to liver steatosis (CPT1A, FASN, LEPR, RXRA, IGFBP1, PPARGC1A and SLC2A4) was detected in our rhesus model, as was the down-regulation of such genes (CYP7A1, HMGCR, GCK and PNPLA3) and the up-regulation of expression of hepatic genes related to liver cancer (E2F1, OPCML, FZD7, IGFBP1 and LEF1).
|
26442469 |
2015 |
|
Steatohepatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The up-regulation of expression of hepatic genes related to liver steatosis (CPT1A, FASN, LEPR, RXRA, IGFBP1, PPARGC1A and SLC2A4) was detected in our rhesus model, as was the down-regulation of such genes (CYP7A1, HMGCR, GCK and PNPLA3) and the up-regulation of expression of hepatic genes related to liver cancer (E2F1, OPCML, FZD7, IGFBP1 and LEF1).
|
26442469 |
2015 |
|
Gall Bladder Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The significant difference of methylation levels of OPCML and HOXD9 was observed in serum cfDNA of CCA compared to other biliary diseases.
|
30832707 |
2019 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
LHGDN |
The results were confirmed at the level of mRNA and protein, and suggested that four genes (OPCML, RNASE1, YES1 and ACK1) could play a key role in the tumorigenesis and metastasis of gastric cancer.
|
17109515 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results showed that, nine genes (APC, CDH13, KLK10, DLEC1, RASSF1A, EFEMP1, SFRP1, RARβ and p16(INK4A)) demonstrated a significantly higher frequency of methylation in NSCLC compared with the normal tissues (P≤0.001), while the others (RUNX3, hMLH1, DAPK, BRCA1, p14(ARF), MGMT, NORE1A, FHIT, CMTM3, LSAMP and OPCML) showed relatively low sensitivity or specificity.
|
21255913 |
2011 |